Back to Search
Start Over
Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment.
- Source :
- Ocular Immunology & Inflammation; Apr2017, Vol. 25 Issue 2, p215-220, 6p
- Publication Year :
- 2017
-
Abstract
- <bold>Purpose: </bold>To analyze the efficacy of tocilizumab in uveitic macular edema (ME) resistant to various immunomodulatory drugs.<bold>Methods: </bold>Patients received tocilizumab every 4 weeks intravenously. Central foveal thickness (CFT) was assessed by optical coherence tomography (OCT).<bold>Results: </bold>Five patients (8 eyes) who were ineffectively pretreated with systemic prednisolone, at least one immunosuppressive drug, and at least one biologic drug for uveitic macular edema were included in the study. At 3 months, a response of ME (≥25% reduction in CFT) was observed in 6 eyes (75.0%) of 5 patients. During follow-up, complete resolution of ME was achieved in 5 eyes (62.5%) of 4 patients. Improvement of BCVA was observed in 3 eyes of 3 patients, and stabilization in 3 eyes of 3 patients. Tocilizumab was well tolerated, and no severe side effects occurred.<bold>Conclusions: </bold>Treatment with tocilizumab can be considered in chronic uveitic macular edema even if previous immunomodulatory therapy has failed. [ABSTRACT FROM AUTHOR]
- Subjects :
- TOCILIZUMAB
EDEMA
METABOLIC disorder treatment
RETINAL diseases
DRUG efficacy
OPTICAL coherence tomography
THERAPEUTIC use of glucocorticoids
THERAPEUTIC use of monoclonal antibodies
IMMUNOSUPPRESSIVE agents
ANGIOGRAPHY
CLINICAL trials
INTRAVENOUS therapy
LONGITUDINAL method
RETINAL degeneration
UVEITIS
VISUAL acuity
TREATMENT effectiveness
RETROSPECTIVE studies
Subjects
Details
- Language :
- English
- ISSN :
- 09273948
- Volume :
- 25
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Ocular Immunology & Inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 122543133
- Full Text :
- https://doi.org/10.3109/09273948.2015.1099680